GMAB
Genmab A/SBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
GMAB vs peer average
62/100
GMAB vs. peer average (B vs. C)
Grade spread
A 3 · C 4 · F 2
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
GILD is the first available peer comparator.
Gilead offers a broader oncology/biopharma benchmark with a much larger commercial base; it is useful for comparing product-mix durability, but Genmab's royalty model is more concentrated.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GMAB
Genmab A/S
GILD
Gilead Sciences
Grade
B
C
Momentum
28
35
Value
64
64
Sentiment
92
61
Setup Bias
Net Bearish
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs GILD
GMAB / GILD
Grade Position
In line
GMAB vs. peer average (B vs. C)
62/100
Momentum
28
GILDValue
64
GILDSentiment
92
GMABRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GMAB
GILD is the first peer returned for this comparison set.